List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4479101/publications.pdf Version: 2024-02-01

313 papers	24,337 citations	4960 84 h-index	9345 143 g-index
321	321	321	25048
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry. Journal of Clinical Oncology, 2005, 23, 1803-1810.	1.6	1,050
2	Immunotherapy in colorectal cancer: rationale, challenges and potential. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 361-375.	17.8	1,039
3	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	16.8	589
4	PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine, 2022, 386, 2363-2376.	27.0	588
5	Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome. Journal of Molecular Diagnostics, 2008, 10, 293-300.	2.8	549
6	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	7.1	426
7	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncology, 2018, 4, e180071.	7.1	404
8	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	1.6	397
9	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	7.0	390
10	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. Journal of Clinical Oncology, 2014, 32, 513-518.	1.6	375
11	Operative Blood Loss Independently Predicts Recurrence and Survival After Resection of Hepatocellular Carcinoma. Annals of Surgery, 2009, 249, 617-623.	4.2	355
12	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncology, 2019, 5, e185896.	7.1	347
13	Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer. Annals of Surgery, 2005, 241, 829-838.	4.2	341
14	A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019, 25, 1607-1614.	30.7	320
15	Long-term Survival Following Treatment of Pseudomyxoma Peritonei. Annals of Surgery, 2005, 241, 300-308.	4.2	302
16	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biology, 2014, 15, 454.	8.8	296
17	Pathologic Classification and Clinical Behavior of the Spectrum of Goblet Cell Carcinoid Tumors of the Appendix. American Journal of Surgical Pathology, 2008, 32, 1429-1443.	3.7	284
18	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	7.0	281

#	Article	IF	CITATIONS
19	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	9.4	275
20	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	1.6	254
21	Individualized Prediction of Colon Cancer Recurrence Using a Nomogram. Journal of Clinical Oncology, 2008, 26, 380-385.	1.6	244
22	Rate of Pathologic Complete Response With Increased Interval Between Preoperative Combined Modality Therapy and Rectal Cancer Resection. Diseases of the Colon and Rectum, 2004, 47, 279-286.	1.3	234
23	Relationship of Gene Expression and Chromosomal Abnormalities in Colorectal Cancer. Cancer Research, 2006, 66, 2129-2137.	0.9	231
24	Pathologic stage is most prognostic of diseaseâ€free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer, 2008, 113, 57-64.	4.1	228
25	Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy. Diseases of the Colon and Rectum, 2008, 51, 503-507.	1.3	211
26	Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precision Oncology, 2017, 2017, 1-17.	3.0	209
27	Sphincter Preservation in Low Rectal Cancer is Facilitated by Preoperative Chemoradiation and Intersphincteric Dissection. Annals of Surgery, 2009, 249, 236-242.	4.2	206
28	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	1.6	204
29	Value of Histopathology in Predicting Microsatellite Instability in Hereditary Nonpolyposis Colorectal Cancer and Sporadic Colorectal Cancer. American Journal of Surgical Pathology, 2003, 27, 1407-1417.	3.7	200
30	Patterns of Morphologic Alteration in Residual Rectal Carcinoma Following Preoperative Chemoradiation and Their Association With Long-term Outcome. American Journal of Surgical Pathology, 2004, 28, 215-223.	3.7	182
31	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. Journal of the National Cancer Institute, 2014, 106, .	6.3	179
32	Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities. American Journal of Surgical Pathology, 2009, 33, 925-933.	3.7	178
33	BLM Heterozygosity and the Risk of Colorectal Cancer. Science, 2002, 297, 2013-2013.	12.6	174
34	Pathogenesis of Colloid (Pure Mucinous) Carcinoma of Exocrine Organs. American Journal of Surgical Pathology, 2003, 27, 571-578.	3.7	171
35	Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity?. American Journal of Surgical Pathology, 2008, 32, 719-731.	3.7	166
36	Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer, 2010, 116, 1502-1509.	4.1	165

#	Article	IF	CITATIONS
37	A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer. PLoS ONE, 2012, 7, e45357.	2.5	164
38	Clinical Examination Following Preoperative Chemoradiation for Rectal Cancer Is Not a Reliable Surrogate End Point. Journal of Clinical Oncology, 2005, 23, 3475-3479.	1.6	161
39	A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography. Annals of Surgical Oncology, 2006, 13, 1047-1053.	1.5	160
40	The Role of Abdominoperineal Resection as Surgical Therapy for Anorectal Melanoma. Annals of Surgery, 2006, 244, 1012-1017.	4.2	159
41	KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases. Annals of Surgical Oncology, 2010, 17, 572-578.	1.5	159
42	Resection Margin and Survival in 2368 Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2015, 262, 476-485.	4.2	156
43	Primary Follicular Lymphoma of the Gastrointestinal Tract. American Journal of Surgical Pathology, 2002, 26, 216-224.	3.7	155
44	Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. American Journal of Surgical Pathology, 2009, 33, 1639-1645.	3.7	155
45	Lymph node metastasis in T1 adenocarcinoma of the colon and rectum. Journal of Gastrointestinal Surgery, 2004, 8, 1032-1040.	1.7	154
46	Prognostic Significance of Localized Extra-appendiceal Mucin Deposition in Appendiceal Mucinous Neoplasms. American Journal of Surgical Pathology, 2009, 33, 248-255.	3.7	154
47	Surgical Salvage of Recurrent Rectal Cancer After Transanal Excision. Diseases of the Colon and Rectum, 2005, 48, 1169-1175.	1.3	153
48	Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Letters, 2007, 248, 219-228.	7.2	153
49	Long-Term Survival After Transanal Excision of T1 Rectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 577-582.	1.3	151
50	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Modern Pathology, 2005, 18, 1350-1356.	5.5	146
51	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	5.5	144
52	Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Human Pathology, 2008, 39, 116-125.	2.0	143
53	Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2013, 20, 946-955.	1.5	141
54	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. Nature Cancer, 2020, 1, 28-45.	13.2	137

#	Article	IF	CITATIONS
55	Value of Immunohistochemical Detection of DNA Mismatch Repair Proteins in Predicting Germline Mutation in Hereditary Colorectal Neoplasms. American Journal of Surgical Pathology, 2005, 29, 96-104.	3.7	136
56	Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chinese Clinical Oncology, 2016, 5, 62-62.	1.2	131
57	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4240-4246.	1.6	129
58	Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Human Pathology, 2010, 41, 643-652.	2.0	128
59	<i>KRAS</i> mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer, 2014, 120, 3965-3971.	4.1	127
60	Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer, 2005, 104, 1948-1955.	4.1	123
61	A Prospective Pathologic Analysis Using Whole-Mount Sections of Rectal Cancer Following Preoperative Combined Modality Therapy. Annals of Surgery, 2007, 245, 88-93.	4.2	123
62	A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum. Annals of Surgical Oncology, 2014, 21, 2956-2962.	1.5	123
63	Utility of Immunohistochemistry in Predicting Microsatellite Instability in Endometrial Carcinoma. American Journal of Surgical Pathology, 2007, 31, 744-751.	3.7	121
64	Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy. Oncologist, 2011, 16, 1714-1720.	3.7	121
65	Operative Salvage for Locoregional Recurrent Colon Cancer After Curative Resection: An Analysis of 100 Cases. Diseases of the Colon and Rectum, 2005, 48, 897-909.	1.3	119
66	Extranodal follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic characteristics of an underrecognized disease entity. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 148-158.	2.8	118
67	Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	7.0	118
68	T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2009, 16, 2524-2530.	1.5	116
69	A Novel Prognostic Nomogram Is More Accurate than Conventional Staging Systems for Predicting Survival after Resection of Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2008, 206, 281-291.	0.5	114
70	The Utility of Immunohistochemistry in Subtyping Adenocarcinoma of the Ampulla of Vater. American Journal of Surgical Pathology, 2014, 38, 1371-1379.	3.7	113
71	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Research, 2019, 79, 1047-1053.	0.9	112
72	Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3925-3930.	3.6	106

#	Article	IF	CITATIONS
73	Immunohistochemical expression of folate receptor $\hat{I}\pm$ in colorectal carcinoma: patterns and biological significance. Human Pathology, 2008, 39, 498-505.	2.0	102
74	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. Diseases of the Colon and Rectum, 2008, 51, 147-153.	1.3	100
75	The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 431-441.	2.8	96
76	Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Annals of Surgery, 2013, 258, 289-295.	4.2	94
77	HER 2/neu expression and gene amplification in colon cancer. International Journal of Cancer, 2003, 105, 796-802.	5.1	93
78	Limitations of Early Rectal Cancer Nodal Staging may Explain Failure after Local Excision. Diseases of the Colon and Rectum, 2007, 50, 1520-1525.	1.3	93
79	Unusual DNA mismatch repair–deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Human Pathology, 2012, 43, 1677-1687.	2.0	93
80	Increased Endocrine Cells in Treated Rectal Adenocarcinomas. American Journal of Surgical Pathology, 2002, 26, 863-872.	3.7	91
81	Prognostic Implications of the Distribution of Lymph Node Metastases in Rectal Cancer After Neoadjuvant Chemoradiotherapy. Journal of Clinical Oncology, 2008, 26, 2106-2111.	1.6	90
82	Significance of Acellular Mucin Pools in Rectal Carcinoma After Neoadjuvant Chemoradiotherapy. American Journal of Surgical Pathology, 2011, 35, 127-134.	3.7	90
83	DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Modern Pathology, 2020, 33, 648-656.	5.5	90
84	Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Familial Cancer, 2013, 12, 241-260.	1.9	88
85	Squamous-Cell Carcinoma of the Rectum: A Rare but Curable Tumor. Diseases of the Colon and Rectum, 2007, 50, 1393-1400.	1.3	87
86	Preoperative Radiographic Assessment of Hepatic Steatosis with Histologic Correlation. Journal of the American College of Surgeons, 2008, 206, 480-488.	0.5	87
87	p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Modern Pathology, 2010, 23, 80-92.	5.5	87
88	Carcinoid of the Rectum Risk Stratification (CaRRs): A Strategy for Preoperative Outcome Assessment. Annals of Surgical Oncology, 2007, 14, 1735-1743.	1.5	86
89	Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients. Journal of General Virology, 2016, 97, 2291-2300.	2.9	85
90	Defining Surgical Indications for Type I Gastric Carcinoid Tumor. Annals of Surgical Oncology, 2009, 16, 3154-3160.	1.5	84

#	Article	IF	CITATIONS
91	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 319-324.	3.7	83
92	Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma. American Journal of Surgical Pathology, 2011, 35, 447-454.	3.7	82
93	Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Modern Pathology, 2013, 26, 131-138.	5.5	82
94	Predictors of Recurrence in Patients With T2 and Early T3, N0 Adenocarcinoma of the Rectum Treated by Surgery Alone. Journal of Clinical Oncology, 2006, 24, 4078-4084.	1.6	80
95	Challenging the Feasibility and Clinical Significance of Current Guidelines on Lymph Node Examination in Rectal Cancer in the Era of Neoadjuvant Therapy. Journal of Clinical Oncology, 2011, 29, 4568-4573.	1.6	80
96	Residual Mesorectal Lymph Node Involvement Following Neoadjuvant Combined-Modality Therapy: Rationale for Radical Resection?. Annals of Surgical Oncology, 2004, 11, 187-191.	1.5	79
97	Histologic Classification of Tumor-Infiltrating Lymphocytes in Primary Cutaneous Malignant Melanoma. American Journal of Clinical Pathology, 2001, 115, 856-860.	0.7	77
98	Distinction of endometrial stromal sarcomas from â€~hemangiopericytomatous' tumors using a panel of immunohistochemical stains. Modern Pathology, 2005, 18, 40-47.	5.5	77
99	Preoperative Chemotherapy and the Risk of Hepatotoxicity and Morbidity after Liver Resection for Metastatic Colorectal Cancer: A Single Institution Experience. Journal of the American College of Surgeons, 2013, 216, 41-49.	0.5	77
100	Towards Identification of Hereditary DNA Mismatch Repair Deficiency: Sebaceous Neoplasm Warrants Routine Immunohistochemical Screening Regardless of Patient's Age or Other Clinical Characteristics. American Journal of Surgical Pathology, 2009, 33, 934-944.	3.7	76
101	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. Annals of Surgical Oncology, 2011, 18, 2192-2199.	1.5	76
102	Rate of Residual Disease After Complete Endoscopic Resection of Malignant Colonic Polyp. Diseases of the Colon and Rectum, 2012, 55, 122-127.	1.3	75
103	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology–molecular associations: clinical and biological implications. Modern Pathology, 2017, 30, 599-609.	5.5	74
104	Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight, 2018, 3, .	5.0	73
105	Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. Journal of Pediatric Surgery, 2016, 51, 1812-1817.	1.6	72
106	Carcinoid of the Rectum Risk Stratification (CaRRS): A Strategy for Preoperative Outcome Assessment. Annals of Surgical Oncology, 2007, 14, 396-404.	1.5	71
107	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Clinical Cancer Research, 2019, 25, 1948-1956.	7.0	71
108	An Update on Tumors of the Anal Canal. Archives of Pathology and Laboratory Medicine, 2010, 134, 1601-1611.	2.5	68

#	Article	IF	CITATIONS
109	What is the Significance of the Circumferential Margin in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy?. Annals of Surgical Oncology, 2013, 20, 1179-1184.	1.5	66
110	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
111	Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 523-532.	2.8	65
112	Effects of Obesity in Rectal Cancer Surgery. Journal of the American College of Surgeons, 2010, 211, 55-60.	0.5	64
113	Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?. Annals of Surgical Oncology, 2012, 19, 2643-2651.	1.5	64
114	Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer. Annals of Surgery, 2012, 256, 111-116.	4.2	63
115	Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. Annals of Surgical Oncology, 2017, 24, 1835-1842.	1.5	61
116	Poorly Differentiated Clusters Predict Colon Cancer Recurrence. American Journal of Surgical Pathology, 2018, 42, 705-714.	3.7	61
117	Majority of <i>B2M</i> -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precision Oncology, 2019, 3, 1-14.	3.0	61
118	Deciduoid Mesothelioma: A Report of 5 Cases and Literature Review. Ultrastructural Pathology, 2002, 26, 355-363.	0.9	59
119	Virus-Associated Trichodysplasia Spinulosa. American Journal of Surgical Pathology, 2005, 29, 241-246.	3.7	59
120	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Modern Pathology, 2020, 33, 871-879.	5.5	58
121	Lymph Node Staging in Colorectal Cancer: Revisiting the Benchmark of at Least 12 Lymph Nodes in RO Resection. Journal of the American College of Surgeons, 2012, 214, 348-355.	0.5	57
122	GROα Is Highly Expressed in Adenocarcinoma of the Colon and Down-Regulates Fibulin-1. Clinical Cancer Research, 2006, 12, 5951-5959.	7.0	54
123	MSH6 germline mutations are rare in colorectal cancer families. International Journal of Cancer, 2003, 107, 571-579.	5.1	53
124	Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome. Annals of Surgical Oncology, 2012, 19, 2797-2804.	1.5	53
125	The Prevalence of Thyroid Cancer and Benign Thyroid Disease in Patients With Familial Adenomatous Polyposis May Be Higher Than Previously Recognized. Clinical Colorectal Cancer, 2012, 11, 304-308.	2.3	52
126	Management and Outcome of Perianal Paget's Disease. Diseases of the Colon and Rectum, 2014, 57, 747-751.	1.3	52

#	Article	IF	CITATIONS
127	The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. Journal of Translational Medicine, 2015, 13, 199.	4.4	52
128	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Modern Pathology, 2015, 28, 1123-1129.	5.5	51
129	A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or) Tj ETQq1 1 0.784314	rgBT /Ove	erlock 10 Tf
130	Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. PLoS ONE, 2015, 10, e0132953.	2.5	50
131	Folate receptor- \hat{l}_{\pm} expression in resectable hepatic colorectal cancer metastases: patterns and significance. Modern Pathology, 2011, 24, 1221-1228.	5.5	48
132	The Signatures of Autozygosity among Patients with Colorectal Cancer. Cancer Research, 2008, 68, 2610-2621.	0.9	47
133	Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Seminars in Diagnostic Pathology, 2015, 32, 352-361.	1.5	47
134	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	3.4	46
135	A Predictive Model for Lymph Node Yield in Colon Cancer Resection Specimens. Annals of Surgery, 2011, 253, 318-322.	4.2	45
136	Locoregional Lymphadenectomy in the Surgical Management of Anorectal Melanoma. Annals of Surgical Oncology, 2013, 20, 2339-2344.	1.5	45
137	Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2017, 24, 2482-2490.	1.5	45
138	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	21.4	44
139	DNA Mismatch Repair Deficiency in Breast Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1700-1708.	3.7	43
140	CXCR4 Expression Predicts Patient Outcome and Recurrence Patterns after Hepatic Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2012, 19, 339-346.	1.5	43
141	Detailed Pathologic Characteristics of the Primary Colorectal Tumor Independently Predict Outcome after Hepatectomy for Metastases. Annals of Surgical Oncology, 2013, 20, 148-154.	1.5	43
142	Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases. Cancer Immunology Research, 2014, 2, 530-537.	3.4	43
143	Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer, 2017, 123, 1134-1143.	4.1	43
144	Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Human Pathology, 2014, 45, 2430-2436.	2.0	41

#	Article	IF	CITATIONS
145	A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2016, 22, 2575-2582.	7.0	40
146	Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncology, The, 2005, 6, 438-439.	10.7	39
147	DNA Mismatch Repair Deficiency in Ampullary Carcinoma. American Journal of Clinical Pathology, 2010, 133, 772-780.	0.7	38
148	Whole-Mount Pathologic Analysis of Rectal Cancer Following Neoadjuvant Therapy. Annals of Surgery, 2012, 256, 274-279.	4.2	38
149	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 207-212.	2.3	37
150	Gastric Carcinomas With Lymphoid Stroma. American Journal of Surgical Pathology, 2018, 42, 453-462.	3.7	37
151	Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer. Journal of Surgical Oncology, 2016, 114, 637-641.	1.7	35
152	Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer, 2006, 106, 1857-1862.	4.1	34
153	Evaluation of 18F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis. Annals of Surgical Oncology, 2011, 18, 2783-2789.	1.5	34
154	DNA Mismatch Repair Abnormalities in Acinar Cell Carcinoma of the Pancreas. Pancreas, 2014, 43, 1264-1270.	1.1	34
155	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. Journal of Clinical Oncology, 2021, 39, 911-919.	1.6	34
156	Idiopathic Cholestasis as a Paraneoplastic Phenomenon in Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2006, 7, 77-82.	1.4	33
157	Does Gadolinium-Based Contrast Material Improve Diagnostic Accuracy of Local Invasion in Rectal Cancer MRI? A Multireader Study. American Journal of Roentgenology, 2015, 204, W160-W167.	2.2	33
158	Gene Expression Profiles Accurately Predict Outcome Following Liver Resection in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e81680.	2.5	33
159	Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Chinese Clinical Oncology, 2016, 5, 66-66.	1.2	33
160	Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance. Human Pathology, 2005, 36, 845-849.	2.0	32
161	Systematic Immunohistochemistry Screening for Lynch Syndrome in Early Age-of-Onset Colorectal Cancer Patients Undergoing Surgical Resection. Journal of the American College of Surgeons, 2012, 214, 61-67.	0.5	32
162	The diversity of tumours with microsatellite instability: molecular mechanisms and impact upon microsatellite instability testing and mismatch repair protein immunohistochemistry. Histopathology, 2021, 78, 485-497.	2.9	32

#	Article	IF	CITATIONS
163	Imaging and Clinicopathologic Features of Esophageal Gastrointestinal Stromal Tumors. American Journal of Roentgenology, 2014, 203, 306-314.	2.2	30
164	Genetic Evidence That Intratumoral T-cell Proliferation and Activation Are Associated with Recurrence and Survival in Patients with Resected Colorectal Liver Metastases. Cancer Immunology Research, 2015, 3, 380-388.	3.4	30
165	Chemotherapy-Induced Splenic Volume Increase Is Independently Associated with Major Complications after Hepatic Resection for Metastatic Colorectal Cancer. Journal of the American College of Surgeons, 2015, 220, 271-280.	0.5	30
166	Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 447, 828-834.	2.8	29
167	The Activity of Sunitinib against Gastrointestinal Stromal Tumor Seems to be Distinct from Its Antiangiogenic Effects: Fig. 1 Clinical Cancer Research, 2006, 12, 6203-6204.	7.0	29
168	Expression of Markers of Hepatocellular Differentiation in Pancreatic Acinar Cell Neoplasms. American Journal of Clinical Pathology, 2016, 146, 163-169.	0.7	28
169	EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathology and Oncology Research, 2017, 23, 673-677.	1.9	28
170	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Modern Pathology, 2019, 32, 110-121.	5.5	28
171	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer, 2019, 125, 1441-1448.	4.1	28
172	Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study. JNCI Cancer Spectrum, 2021, 5, pkab026.	2.9	28
173	Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case. Familial Cancer, 2015, 14, 61-68.	1.9	27
174	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27
175	Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. Clinical and Experimental Metastasis, 2020, 37, 593-605.	3.3	27
176	Differential expression of α-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance. Human Pathology, 2007, 38, 850-856.	2.0	26
177	FDG-PET Assessment of Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Is Not Associated With Long-Term Prognosis. Diseases of the Colon and Rectum, 2012, 55, 378-386.	1.3	26
178	Recurrent, truncating <i>SOX9</i> mutations are associated with SOX9 overexpression, <i>KRAS</i> mutation, and <i>TP53</i> wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	1.8	26
179	Lymphohistiocytoid Mesothelioma: A Clinical, Immunohistochemical and Ultrastructural Study of Four Cases and Literature Review. Ultrastructural Pathology, 2004, 28, 213-228.	0.9	25
180	Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome. Annals of Surgical Oncology, 2004, 11, 955-961.	1.5	24

#	Article	IF	CITATIONS
181	TNM staging of colorectal carcinoma: issues and caveats. Seminars in Diagnostic Pathology, 2012, 29, 142-153.	1.5	24
182	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research, 2017, 15, 708-713.	3.4	24
183	Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. Oncotarget, 2016, 7, 2159-2174.	1.8	24
184	Whorls of Intermediate Filaments With Entrapped Neurosecretory Granules Correspond to the "Rhabdoid―Inclusions Seen in Pancreatic Endocrine Neoplasms. American Journal of Surgical Pathology, 2004, 28, 271-273.	3.7	23
185	High-grade dysplasia of the cystic duct margin in the absence of malignancy after cholecystectomy. Hpb, 2011, 13, 865-868.	0.3	23
186	Hypoxia-Related Proteins in Patients With Rectal Cancer Undergoing Neoadjuvant Combined Modality Therapy. Diseases of the Colon and Rectum, 2012, 55, 990-995.	1.3	23
187	Histopathological growth patterns and positive margins after resection of colorectal liver metastases. Hpb, 2020, 22, 911-919.	0.3	23
188	Characterization and Clinical Outcomes of DNA Mismatch Repair–deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	7.0	23
189	Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases. Journal of Pathology: Clinical Research, 2022, 8, 48-64.	3.0	23
190	Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy. International Journal of Colorectal Disease, 2008, 23, 243-249.	2.2	22
191	Clinicopathologic Analysis of Matched Primary and Recurrent Endometrial Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1771-1781.	3.7	22
192	Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. Modern Pathology, 2013, 26, 1197-1203.	5.5	22
193	Sclerosed hemangioma of the liver: Concordance of MRI features with histologic characteristics. Journal of Magnetic Resonance Imaging, 2014, 39, 812-818.	3.4	22
194	CT Colonography in Preoperative Staging of Colon Cancer: Evaluation of FOxTROT Inclusion Criteria for Neoadjuvant Therapy. American Journal of Roentgenology, 2019, 212, 94-102.	2.2	22
195	STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability. PLoS ONE, 2020, 15, e0229252.	2.5	22
196	Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. Annals of Surgical Oncology, 2019, 26, 2821-2830.	1,5	21
197	FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. Clinical Colorectal Cancer, 2019, 18, e39-e52.	2.3	21
198	Intramucosal Poorly Differentiated Colorectal Carcinoma: Can it be Managed Conservatively?. American Journal of Surgical Pathology, 2008, 32, 1586-1588.	3.7	20

#	Article	IF	CITATIONS
199	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. Molecular Cancer Research, 2015, 13, 1003-1008.	3.4	20
200	Adenocarcinoma of the Minor Duodenal Papilla and Its Precursor Lesions. American Journal of Surgical Pathology, 2014, 38, 526-533.	3.7	19
201	MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. Oncotarget, 2017, 8, 18821-18831.	1.8	19
202	Predictive Molecular Markers for Colorectal Cancer Patients With Resected Liver Metastasis and Adjuvant Chemotherapy. Gastroenterology, 2007, 133, 1831-1839.	1.3	18
203	Scirrhous Metastases to the Gastrointestinal Tract at CT: The Malignant Target Sign. American Journal of Roentgenology, 2009, 192, 936-940.	2.2	18
204	Imaging and management of a small cell lung cancer metastasis/adrenal adenoma collision tumor: a case report and review of the literature. World Journal of Surgical Oncology, 2014, 12, 45.	1.9	18
205	ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. Human Pathology, 2016, 53, 97-104.	2.0	18
206	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. Familial Cancer, 2017, 16, 525-529.	1.9	18
207	Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits. Annals of Surgical Oncology, 2019, 26, 118-124.	1.5	18
208	Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant <i>POLE/POLD1</i> Colon Cancer. JCO Precision Oncology, 2021, 5, 817-826.	3.0	18
209	Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 438-443.	1.2	17
210	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Human Pathology, 2017, 62, 74-82.	2.0	17
211	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. Familial Cancer, 2018, 17, 225-228.	1.9	17
212	Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patients. Pediatric Radiology, 2011, 41, 335-340.	2.0	16
213	Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Appendiceal Mucinous Neoplasms With Isolated Peritoneal Metastasis. Diseases of the Colon and Rectum, 2012, 55, 407-415.	1.3	16
214	The accuracy of pre-operative imaging in the management of hepatic cysts. Hpb, 2015, 17, 889-895.	0.3	16
215	Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. Oncolmmunology, 2018, 7, e1435227.	4.6	16
216	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. JNCI Cancer Spectrum, 2019, 3, pkz015.	2.9	16

#	Article	IF	CITATIONS
217	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Network Open, 2021, 4, e2133457.	5.9	16
218	Feasibility of ex Vivo FDG PET of the Colon. Radiology, 2009, 252, 232-239.	7.3	15
219	Improved Testing for Microsatellite Instability in Colorectal Cancer Using a Simplified 3-Marker Assay. Annals of Surgical Oncology, 2010, 17, 3370-3378.	1.5	15
220	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	12.8	15
221	Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. Familial Cancer, 2014, 13, 459-467.	1.9	14
222	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. Human Pathology, 2019, 83, 1-6.	2.0	14
223	Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 130-133.	4.9	14
224	Molecular Screening for Lynch Syndrome in Young Patients With Colorectal Adenomas. Clinical Colorectal Cancer, 2017, 16, 173-177.	2.3	13
225	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2020, 25, e1825-e1836.	3.7	13
226	Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases. Modern Pathology, 2020, 33, 1410-1419.	5.5	13
227	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. Clinical Cancer Research, 2022, 28, 404-413.	7.0	13
228	Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?. Modern Pathology, 2022, 35, 1515-1528.	5.5	13
229	An Increasingly Common Challenge: Management of the Complete Responder With Multi-Focal Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 1799-1802.	1.6	12
230	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. Modern Pathology, 2019, 32, 1551-1562.	5.5	12
231	DEAD-box RNA helicase protein DDX21 as a prognosis marker for early stage colorectal cancer with microsatellite instability. Scientific Reports, 2020, 10, 22085.	3.3	12
232	Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. Modern Pathology, 2022, 35, 564-576.	5.5	12
233	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Oncologist, 2022, 27, 380-388.	3.7	12
234	Single-amplicon MSH2 A636P Mutation Testing in Ashkenazi Jewish Patients With Colorectal Cancer. Annals of Surgery, 2007, 245, 560-565.	4.2	11

#	Article	lF	CITATIONS
235	Expression of P53, P27 and Klâ€67 in colorectal cancer patients of various ethnic origins: Clinical and tissue microarray based analysis. Journal of Surgical Oncology, 2008, 97, 416-422.	1.7	11
236	Synchronous Breast Cancers With Different Morphologic and Molecular Phenotypes Occurring in Lynch Syndrome. American Journal of Surgical Pathology, 2011, 35, 1743-1748.	3.7	11
237	Patients With Colorectal and Renal Cell Carcinoma Diagnoses Appear to Be at Risk for Additional Malignancies. Clinical Colorectal Cancer, 2013, 12, 23-27.	2.3	11
238	Lymph Node Yield After Colectomy for Cancer. Diseases of the Colon and Rectum, 2015, 58, 288-293.	1.3	11
239	Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis?. American Journal of Surgical Pathology, 2018, 42, 1390-1395.	3.7	11
240	Acellular mucin in pseudomyxoma peritonei of appendiceal origin: what is adequate sampling for histopathology?. Journal of Clinical Pathology, 2020, 73, 220-222.	2.0	11
241	Maspin as a Prognostic Marker for Early Stage Colorectal Cancer With Microsatellite Instability. Frontiers in Oncology, 2020, 10, 945.	2.8	11
242	Collision Tumor of the Large Bowel in the Context of Advanced Pregnancy and Ulcerative Colitis. Clinical Colorectal Cancer, 2008, 7, 402-405.	2.3	10
243	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Familial Cancer, 2018, 17, 71-77.	1.9	10
244	Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. European Radiology, 2019, 29, 458-467.	4.5	10
245	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	3.0	10
246	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget, 2017, 8, 42487-42494.	1.8	10
247	CASE REPORT: Ileal Diverticulitis: Clinical and Radiographic Presentation. Digestive Diseases and Sciences, 2004, 49, 498-502.	2.3	9
248	Juvenile Polyposis Syndrome Presenting With Familial Gastric Cancer and Massive Gastric Polyposis. Journal of Clinical Oncology, 2012, 30, e229-e232.	1.6	9
249	Utilization of Colonoscopy and Pathology Reports for Identifying Patients Meeting the World Health Organization Criteria for Serrated Polyposis Syndrome. Diseases of the Colon and Rectum, 2014, 57, 846-850.	1.3	9
250	Clinicopathologic Features of Colorectal Carcinoma in HIV-Positive Patients. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1098-1104.	2.5	9
251	Pathology definitions and resection strategies for early colorectal neoplasia: Eastern versus Western approaches in the post-Vienna era. Gastrointestinal Endoscopy, 2020, 91, 983-988.	1.0	9
252	Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs. Modern Pathology, 2022, 35, 554-563.	5.5	9

#	Article	IF	CITATIONS
253	MRI at Restaging After Neoadjuvant Therapy for Rectal Cancer Overestimates Circumferential Resection Margin Proximity as Determined by Comparison With Whole-Mount Pathology. Diseases of the Colon and Rectum, 2022, 65, 489-496.	1.3	9
254	Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study. British Journal of Anaesthesia, 2022, 129, 172-181.	3.4	9
255	Liver angiomyolipomas: A clinical, radiologic, and pathologic analysis ofÂ22 patients from a single center. Surgery, 2011, 150, 557-567.	1.9	8
256	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Familial Cancer, 2020, 20, 201-213.	1.9	8
257	Effectiveness of a surveillance program of upper endoscopy for upper gastrointestinal cancers in Lynch syndrome patients. International Journal of Colorectal Disease, 2022, 37, 231-238.	2.2	8
258	Response to Neoadjuvant Therapy in Patients With Early Age-of-Onset Rectal Cancer. Diseases of the Colon and Rectum, 2013, 56, 58-63.	1.3	7
259	Evaluation of diffusion kurtosis and diffusivity from baseline staging MRI as predictive biomarkers for response to neoadjuvant chemoradiation in locally advanced rectal cancer. Abdominal Radiology, 2019, 44, 3701-3708.	2.1	7
260	Three-Dimensional Vessel Segmentation in Whole-Tissue and Whole-Block Imaging Using a Deep Neural Network. American Journal of Pathology, 2021, 191, 463-474.	3.8	7
261	KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix. Molecular Oncology, 2021, 15, 2766-2781.	4.6	7
262	Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer. Oncotarget, 2020, 11, 813-824.	1.8	7
263	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195.	2.4	7
264	Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger–Ellison syndromes: case series and literature review. European Journal of Gastroenterology and Hepatology, 2010, 22, 246-252.	1.6	6
265	Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 188-195.	1.5	6
266	Metastatic Epithelioid Gastrointestinal Stromal Tumor: Yet Another Tumor with Anemone Cell Features. Ultrastructural Pathology, 2003, 27, 95-100.	0.9	5
267	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a ¹ H MRS study. NMR in Biomedicine, 2013, 26, 204-212.	2.8	5
268	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. Cancer, 2020, 126, 4126-4135.	4.1	5
269	Clinicopathologic Features of Varicella Zoster Virus Infection of the Upper Gastrointestinal Tract. American Journal of Surgical Pathology, 2021, 45, 209-214.	3.7	5
270	SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate Journal of Clinical Oncology, 2017, 35, 587-587.	1.6	5

#	Article	IF	CITATIONS
271	Liver and Bile Duct Cancer. , 2014, , 1373-1396.e8.		5
272	Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. Journal of Gastrointestinal Oncology, 2017, 8, E65-E72.	1.4	4
273	Hepatocellular carcinoma in patients with no identifiable risk factors. Hpb, 2021, 23, 118-126.	0.3	4
274	Pathological evaluation of a rectal endoscopic submucosal dissection specimen using micro-computed tomography. Endoscopy, 2022, 54, E254-E255.	1.8	4
275	Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, 3519-3519.	1.6	4
276	Pathologic Complete Response to Neoadjuvant FOLFOX in Combination with Bevacizumab in Unresectable Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer, 2008, 7, 140-143.	2.3	3
277	Synchronous Epithelial and Neuroendocrine Cancers of the Pancreas: Case Series of a Rare Occurrence. Clinical Colorectal Cancer, 2011, 10, 146-150.	2.3	3
278	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. Oncolmmunology, 2020, 9, 1841948.	4.6	3
279	Total neoadjuvant therapy for locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, 662-662.	1.6	3
280	Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy. Journal of Immunotherapy, 2021, Publish Ahead of Print, .	2.4	3
281	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. Journal of the National Cancer Institute, 2022, 114, 761-770.	6.3	3
282	Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes. OncoImmunology, 2022, 11, 2054757.	4.6	3
283	p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease. American Journal of Surgery, 2014, 208, 228-234.	1.8	2
284	Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. Journal of Gastrointestinal Surgery, 2019, 23, 794-799.	1.7	2
285	A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS ONE, 2016, 11, e0146435.	2.5	2
286	Carcinosarcoma of the bile duct: a case report and review of literature. Hepatobiliary Surgery and Nutrition, 2016, 5, 72-8.	1.5	2
287	Pathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography. Diagnostics, 2022, 12, 984.	2.6	2
288	A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management. Journal of Gastrointestinal Cancer, 2011, 42, 236-240.	1.3	1

#	Article	IF	CITATIONS
289	Predictive Markers Require Thorough Analytic Validation. Archives of Pathology and Laboratory Medicine, 2019, 143, 907-909.	2.5	1
290	Confirmation of complete mesocolic excision with central vascular ligation. European Journal of Surgical Oncology, 2020, 46, 1386-1387.	1.0	1
291	Reply to Singh et al Modern Pathology, 2021, 34, 1033-1034.	5.5	1
292	Initial evaluation of dual-energy computed tomography as an imaging biomarker for hepatic metastases from neuroendocrine tumor of the gastrointestinal tract. Quantitative Imaging in Medicine and Surgery, 2021, 11, 2085-2092.	2.0	1
293	Identification of a TP53 Deletion in an Undifferentiated Embryonal Sarcoma of the Liver Provides Clinically Relevant Longitudinal Detection of Circulating Tumor DNA. JCO Precision Oncology, 2021, 5, 1421-1425.	3.0	1
294	Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases. Journal of Clinical Oncology, 2013, 31, 3609-3609.	1.6	1
295	Characterization of rectal cancer in patients with Lynch syndrome Journal of Clinical Oncology, 2013, 31, 350-350.	1.6	1
296	Influence of KRAS mutation on recurrence patterns in patients undergoing hepatic resection of colorectal metastases Journal of Clinical Oncology, 2013, 31, 398-398.	1.6	1
297	Evolution in multimodality management of locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, 684-684.	1.6	1
298	OUP accepted manuscript. American Journal of Clinical Pathology, 2021, , .	0.7	1
299	Poorly differentiated clusters as a prognostic marker at the invasive front of colon cancer Journal of Clinical Oncology, 2017, 35, 621-621.	1.6	1
300	Variability in genomic alterations between right- and left-sided microsatellite stable (MSS) metastatic colorectal cancer and impact on survival Journal of Clinical Oncology, 2017, 35, 3534-3534.	1.6	1
301	Identification of a Subset of Stage I Colorectal Cancer Patients with High Recurrence Risk. Journal of the National Cancer Institute, 2022, , .	6.3	1
302	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100365.	3.0	1
303	Micro-computed tomography: A novel diagnostic technique for the evaluation of gastrointestinal specimens. Endoscopy International Open, 2021, 09, E1886-E1889.	1.8	1
304	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. Cancer Medicine, 2022, 11, 602-617.	2.8	1
305	Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup. JCO Precision Oncology, 2022, , .	3.0	1
306	Metastases to the Breast from Primary Pancreatic Cancer. Breast Journal, 2005, 11, 503-503.	1.0	0

#	Article	IF	CITATIONS
307	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. Diseases of the Colon and Rectum, 2008, 51, 620.	1.3	0
308	Concept of Complete Mesocolic Excision and the Role of Computed Tomography Imaging. Seminars in Roentgenology, 2021, 56, 201-205.	0.6	0
309	Is there any significant difference between tumor regression grade systemsÂof rectal cancer?. Journal of Clinical Oncology, 2012, 30, 3583-3583.	1.6	0
310	Characterization of colorectal cancer (CRC) in Lynch syndrome (LS) patients with <i>MSH6</i> or <i>PMS2</i> mutations Journal of Clinical Oncology, 2013, 31, 1555-1555.	1.6	0
311	Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay Journal of Clinical Oncology, 2015, 33, 11071-11071.	1.6	0
312	Institutional variation in the thoroughness of pathologic assessment and pathologic complete response rates for locally advanced rectal cancers treated with neoadjuvant chemoradiation Journal of Clinical Oncology, 2017, 35, 696-696.	1.6	0
313	Acellular mucin in lymph nodes isolated from treatment-naÃ⁻ve colorectal cancer resections: a clinicopathologic analysis of 16 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , .	2.8	0